Skip to main content
Signal8

ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline

$PMNPress releaseNov 17, 2026, 2:30 AM ETRead the release

ProMIS Neurosciences licensed TXP1, a transferrin receptor 1 (TfR1)-targeting brain-selective shuttling technology, from Ossianix for use with its lead Alzheimer's antibody PMN310. In Ossianix preclinical studies, including non-human primate work, TXP1 increased antibody delivery to the brain by more than 65-fold with no off-target accumulation in major organs reported. ProMIS holds options to extend TXP1 to PMN442 (alpha-synuclein/Parkinson's) and PMN267 (TDP-43/ALS), and says the deal does not change its disclosed cash runway through 2027.

Key figures

Cash runway
through 2027
Brain delivery increase
more than 65-fold

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.